Ferrant A - Search Results

1

2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia.

Van Den Neste E, Martiat P, Mineur P, Delannoy A, Doyen C, Zenebergh A, Michaux JL, Ferrant A. Van Den Neste E, et al. Among authors: ferrant a. Ann Hematol. 1998 Jan;76(1):19-23. doi: 10.1007/s002770050355. Ann Hematol. 1998. PMID: 9486920 Clinical Trial.

2

High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of age.

Ferrant A, Doyen C, Delannoy A, Van den Bossche L, Martiat P, Deneys V, De Bruyère M, Bosly A, Michaux JL, Sokal G. Ferrant A, et al. Ann Hematol. 1992 Apr;64(4):185-9. doi: 10.1007/BF01696221. Ann Hematol. 1992. PMID: 1581406

3

Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission.

Ferrant A, Doyen C, Delannoy A, Cornu G, Martiat P, Latinne D, De Bruyère M, Bosly A, Michaux JL, Sokal G. Ferrant A, et al. Bone Marrow Transplant. 1991 Apr;7(4):303-9. Bone Marrow Transplant. 1991. PMID: 2070137

4

High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.

Martiat P, Ghilain JM, Ferrant A, Doyen C, Delannoy A, Chatelain C, Bosly A, Michaux JL, Sokal G. Martiat P, et al. Among authors: ferrant a. Eur J Haematol. 1990 Sep;45(3):164-7. doi: 10.1111/j.1600-0609.1990.tb00445.x. Eur J Haematol. 1990. PMID: 2226729 Clinical Trial.

5

Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome.

Martiat P, Ferrant A, Michaux JL, Sokal G. Martiat P, et al. Among authors: ferrant a. Hematol Oncol. 1988 Oct-Dec;6(4):299-305. doi: 10.1002/hon.2900060405. Hematol Oncol. 1988. PMID: 3181878

6

Cyclosporin A in the treatment of refractory B chronic lymphocytic leukemia (B-CLL).

Van Den Neste E, Maerevoet M, Martiat P, Ferrant A, Delannoy A, Michaux JL. Van Den Neste E, et al. Among authors: ferrant a. Leukemia. 1995 Jun;9(6):1102-3. Leukemia. 1995. PMID: 7596177

7

2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL).

Delannoy A, Martiat P, Gala JL, Deneys V, Ferrant A, Bosly A, Schieff JM, Michaux JL. Delannoy A, et al. Among authors: ferrant a. Leukemia. 1995 Jul;9(7):1130-5. Leukemia. 1995. PMID: 7630184 Clinical Trial.

8

A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.

Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P, et al. Filleul B, et al. Among authors: ferrant a. Leukemia. 1994 Jul;8(7):1153-6. Leukemia. 1994. PMID: 7913513

9

2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.

Delannoy A, Ferrant A, Martiat P, Montfort L, Doyen C, Sokal G, Michaux JL. Delannoy A, et al. Among authors: ferrant a. Nouv Rev Fr Hematol (1978). 1994 Aug;36(4):311-5. Nouv Rev Fr Hematol (1978). 1994. PMID: 7971251 Clinical Trial.

10

2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia.

Delannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux JL. Delannoy A, et al. Among authors: ferrant a. Nouv Rev Fr Hematol (1978). 1994 Aug;36(4):317-20. Nouv Rev Fr Hematol (1978). 1994. PMID: 7971252 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

304 results

Search Page

Filters